Adagio Medical Holdings, INC 10-Q quarterly reports

Adagio Medical Holdings, Inc. reported continued net losses and significant cash burn in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, despite advancing its vCLAS Ventricular Ablation System through clinical trials and regulatory submissions.

Adagio Medical Holdings, Inc. reported reduced net losses for the first quarter of 2026 compared to the prior year, driven by decreased operating expenses, though the company continues to face substantial going concern risks.

Adagio Medical Holdings, Inc. reported a significant net loss for Q3 2025, alongside a recent $19 million private placement and progress in its FULCRUM-VT clinical trial.

Adagio Medical Holdings, Inc. reported no revenue for Q2 2025 and expressed substantial doubt about its ability to continue as a going concern, despite receiving FDA Breakthrough Device designation.

Adagio Medical Holdings reports a net loss for Q1 2025 while prioritizing its FULCRUM-VT clinical trial and product design optimization program.

Adagio Medical Holdings reports a net income of $3.6 million for the period from July 31, 2024 to September 30, 2024, following its business combination, but expresses concerns about its ability to continue as a going concern.

Adagio Medical Holdings, formerly Aja Holdco, Inc., completed its business combination and reported a net loss of $2.13 million for the six months ended June 30, 2024.